Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
IONIS PHARMACEUTICALS INC (IONS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/08/2021 |
GN
| TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors |
| 01/08/2021 |
GN
| Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) |
| 06/05/2020 |
GN
| Akcea ? Ionis ?????????? ? ?????????? ???????????? ??????????? ?????? TEGSEDI® ? ????????? ? ???????????????, ????????? ?????????????? ????????????-???????????, ???????????????? ?????????? ????????? ? ???? ??????? ???????????? ? ??????????, ???????????? ? ??????? ?????? ??????. |
| 05/28/2020 |
GN
| Akcea et Ionis annoncent la publication de données cliniques à long terme sur le TEGSEDI® chez des patients atteints de polyneuropathie causée par une amylose héréditaire liée à la transthyrétine démontrant des améliorations durables et une meilleure stabilisation des patients qui débutent le traitement plus tôt |
| 05/28/2020 |
GN
| Akcea und Ionis geben Veröffentlichung klinischer Langzeitdaten zu TEGSEDI® für die Behandlung von Patienten mit Polyneuropathie infolge hereditärer Transthyretin-Amyloidose bekannt, die nachhaltige Verbesserungen und eine noch bessere Stabilisierung bei Patienten mit frühem Behandlungsbeginn zeigen |
| 05/28/2020 |
GN
| Akcea e Ionis annunciano la pubblicazione di dati clinici sull'uso a lungo termine di TEGSEDI® in pazienti con polineuropatia da amiloidosi ereditaria mediata da transtiretina, che dimostrano miglioramenti prolungati e una stabilizzazione ancora maggiore nei pazienti che iniziano il trattamento precocemente |
| 05/28/2020 |
GN
| Akcea e Ionis anuncian la publicación de datos clínicos a largo plazo de TEGSEDI® en pacientes con polineuropatía secundaria a amiloidosis hereditaria mediada por transtirretina en el que se demuestran mejoras continuas y una estabilización aún mayor en pacientes que empiezan el tratamiento temprano |
| 05/28/2020 |
GN
| Akcea en Ionis kondigen publicatie aan van klinische langetermijngegevens van TEGSEDI® bij patiënten met polyneuropathie veroorzaakt door hereditaire transthyretine-amyloïdose die aanhoudende verbeteringen en een nog grotere stabilisatie bij patiënten die eerder met de behandeling beginnen, aantoont |
| 05/28/2020 |
GN
| Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment |
| 04/21/2020 |
GN
| Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast |
| 02/26/2020 |
GN
| Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference |
| 01/28/2020 |
GN
| Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx |
| 01/10/2020 |
GN
| Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy |
| 01/02/2020 |
GN
| New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease |
| 12/18/2019 |
GN
| Akcea Retains Rights to AKCEA-APOCIII-LRx |
| 12/04/2019 |
GN
| Akcea Announces Appointment of New Chief Operating Officer |
| 11/25/2019 |
GN
| Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis |
| 09/18/2019 |
GN
| Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients |
| 09/16/2019 |
GN
| Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting |
| 08/29/2019 |
GN
| Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings |
| 08/07/2019 |
GN
| New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome |
| 08/06/2019 |
GN
| Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy |
| 07/01/2019 |
GN
| Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients |
| 06/29/2019 |
GN
| Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy |
| 06/20/2019 |
GN
| Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting |
| 05/28/2019 |
GN
| Akcea Therapeutics to Present at Upcoming Investor Conferences |
| 05/14/2019 |
GN
| Biogen's SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy |
| 05/07/2019 |
GN
| Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union |
| 05/02/2019 |
GN
| Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19) |
| 04/24/2019 |
GN
| Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast |
| 03/15/2019 |
GN
| Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) |
| 03/04/2019 |
GN
| Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape |
| 12/20/2018 |
GN
| New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home — Factors of Influence, Major Initiatives and Sustained Production |
| 11/29/2018 |
GN
| International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product |
|
|
|